MICHAEL PREJEAN: Open Payments
NPI 1215087887 · MAMOU, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$421 in 22 payments from 7 companies in 2025. Trend: 2023 $580 · 2024 $291 · 2025 $421
Food & beverage: $421
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $191 |
| ABBVIE INC. | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Noven Therapeutics, LLC | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
Products named: ARISTADA, LYBALVI, VRAYLAR, UZEDY, FANAPT, Xelstrym, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE.
Industry payments across LA — which companies pay providers there.
